Antifibrotic therapy can extend survival in patients with progressive fibrosing interstitial lung disease (PF-ILD), according to a new study, but it does not necessarily benefit all patients with progressive pulmonary fibrosis (PPF). The new findings... [3628 chars].. reed more
